>

Matthew Walsh - Allergan Plc Chief Financial Officer, Executive Vice President

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 25px;;'>AL</div>
AGN -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  President
Mr. Matthew M. Walsh had been appointed as Chief Financial Officer of the Company, effective February 20, 2018. Prior to joining the Company, Mr. Walsh, 51served as Executive Vice President and Chief Financial Officer of Catalent, a global provider of drug delivery technology and development solutions for drugs, biologics and consumer health products, since 2012 and served as Senior Vice President and Chief Financial Officer of Catalent from 2008 to 2012. Prior to joining Catalent, Mr. Walsh served as President, Chief Financial Officer and Acting Chief Executive Officer of Escala Group, Inc., a global collectibles network and precious metals trader. From 1996 through 2006, Mr. Walsh held a variety of finance leadership roles at GenTek, Inc., an industrial manufacturer, including Vice PresidentFinance Chief Financial Officer, Vice President Treasurer and Group Controller
Age: 51  President Since 2018  CFA    
862 261 7000  http://www.allergan.com
Walsh is a CFA? charterholder who received a MBA from Cornell University, SC Johnson Graduate School of Management, and a BS in Chemical Engineering from Cornell University, College of Engineering.

Matthew Walsh Latest Insider Activity

Management Efficiency

The company has Return on Asset of (0.04) % which means that on every $100 spent on asset it lost $0.04. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (0.07) % meaning that it generated no profit with money invested by stockholders.
The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has Current Ratio of 0.98 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Sean BohenAstrazeneca PLC
2015
Louise MehrotraJohnson Johnson
2013
Emmanuel BlinBristol Myers Squibb Company
2016
Aarti ShahEli Lilly And Company
2018
Rady JohnsonPfizer
2013
Robert DavisMerck Company
2016
James FordGlaxoSmithKline PLC
2018
Sandra LeungBristol Myers Squibb Company
2015
Pam ChengAstrazeneca PLC
2015
Fionnuala WalshEli Lilly And Company
2007
David FredricksonAstrazeneca PLC
2017
Richard DeLucaMerck Company
2011
Adele AmbroseMerck Company
2009
Andre WyssNovartis AG
2016
Charles BancroftBristol Myers Squibb Company
2016
Angela HwangPfizer
2018
Leon WangAstrazeneca PLC
2019
Thomas LynchBristol Myers Squibb Company
2017
Kathryn WengelJohnson Johnson
2018
Frank DAmelioPfizer
2010
Adam SchechterMerck Company
2010

Company Summary

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland. Allergan Plc operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange.Allergan Plc (AGN) is traded on BATS Exchange in USA. It is located in Clonshaugh Business and Technology Park and employs 16,900 people. Allergan Plc is listed under Pharmaceutical Products category by Fama And French industry classification.

Allergan Plc Leadership Team

Matthew Walsh, Chief Financial Officer, Executive Vice PresidentView
Robert Bailey, Chief Legal Officer and Corporate SecretaryView
Robert Stewart, Executive VP and President of Generic and Global OperationsView
Ronald Taylor, Independent DirectorView
Adriane Brown, Independent DirectorView
William Meury, Executive Vice President, Chief Commercial OfficerView
Brenton Saunders, Chairman of the Board, President, Chief Executive OfficerView
Wayne Swanton, Executive Vice President - Global OperationsView
Robert Hugin, Independent DirectorView
Nicholson, Chief R&D OfficerView
Christopher Bodine, Independent DirectorView
Karen Ling, Chief Human Resource Officer, Executive Vice PresidentView
Michael Gallagher, Lead Independent DirectorView
Paul Bisaro, Executive ChairmanView
Thomas Freyman, Independent DirectorView
Catherine Klema, Lead Independent DirectorView
James DArecca, Chief Accounting OfficerView
Christopher Coughlin, Lead Independent DirectorView
Nesli Basgoz, Independent DirectorView
Philippe Schaison, Executive Vice President and President Allergan MedicalView
Maria Hilado, CFO and Executive VPView
Joseph Boccuzi, Independent DirectorView
Patrick OSullivan, Independent DirectorView
Fred Weiss, Independent DirectorView
A Bailey, Executive Vice President, Chief Legal Officer and Corporate SecretaryView
Alex Kelly, Chief Communications OfficerView
CDavid Nicholson, Executive Vice President, Chief R&D OfficerView
Carol Davidson, Independent DirectorView
Michael Greenberg, Independent DirectorView
Ron Taylor, Independent DirectorView
Jonathon Kellerman, Executive Vice President Chief Compliance OfficerView
Paul Navarre, Executive Vice President and President International BrandsView
James Bloem, Independent DirectorView
Karina Calzadilla, IR Contact OfficerView
Peter McDonnell, Independent DirectorView

Stock Performance Indicators

Current Sentiment - AGN

Allergan Plc Investor Sentiment

Predominant part of Macroaxis users are presently bullish on Allergan Plc. What is your sentiment towards investing in Allergan Plc? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Allergan Plc Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Allergan Plc and Astrazeneca PLC. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Bollinger Bands module to use bollinger bands indicator to analyze target price for a given investing horizon.